CDKN2B and coronary artery disorder: In this case-control study of a Chinese population, we found novel associations between CAD development and methylation levels of the CDKN2B-AS1 (ANRIL) promoter region CpG sites, which were significantly correlated with blood glucose and cholesterol levels, respectively.